LOGIN  |  REGISTER
Astria Therapeutics

Varex Imaging to Present at CJS Securities 23rd Annual New Ideas for the New Year Virtual Investor Conference

December 28, 2022 | Last Trade: US$15.59 0.84 -5.11

Varex Imaging Corporation (Nasdaq: VREX) announced today that it is scheduled to present at CJS Securities 23rd Annual New Ideas for the New Year virtual investor conferences. Details are as follows:

CJS Securities 23rd Annual New Ideas for the New Year Conference
Varex will be presenting on Wednesday, January 11, 2023 at 3:45 PM ET.
The listen-only webcast link is: https://wsw.com/webcast/cjs5/vrex/1629129

The company’s Chief Financial Officer, Sam Maheshwari, will provide an overview of Varex’s business. Varex’s presentation will be webcast and accessible to the public via the company's website at vareximaging.com. Replays will be available for 90 days after the presentation at the same website.

About Varex

Varex Imaging Corporation is a leading innovator, designer and manufacturer of X-ray imaging components, which include X-ray tubes, digital detectors and other image processing solutions that are key components of X-ray imaging systems. With a 70+ year history of successful innovation, Varex’s products are used in medical imaging as well as in industrial and security imaging applications. Global OEM manufacturers incorporate Varex’s X-ray sources, digital detectors, connecting devices and imaging software in their systems to detect, diagnose, protect and inspect. Headquartered in Salt Lake City, Utah, Varex employs approximately 2,300 people located in North America, Europe, and Asia. For more information visit vareximaging.com.

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB